| First Author | Grohmann U | Year | 1997 |
| Journal | Cell Immunol | Volume | 181 |
| Issue | 2 | Pages | 109-19 |
| PubMed ID | 9398398 | Mgi Jnum | J:44356 |
| Mgi Id | MGI:1099934 | Doi | 10.1006/cimm.1997.1190 |
| Citation | Grohmann U, et al. (1997) Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells. Cell Immunol 181(2):109-19 |
| abstractText | Previously tumorigenic P815 tumor cells are rejected by histocompatible mice after transfection with a mutated retroviral gene, and the host is made resistant to subsequent challenge with tumorigenic (control) cells transfected with the nonmutated sequence. To functionally characterize the class I-restricted response to the tumor cell vaccine, we have assessed the in vitro (by CD8+ cells) and in vivo production of type 1 or type 2 cytokines in mice injected with either type of transfected P815 derivative. IL-12 and IL-10 were selectively or preferentially expressed by the regressor mice, and this correlated with the detection of functional type 1 reactivity in vivo (i.e., delayed-type hypersensitivity). Other cytokines were produced by the regressor mice only in vitro (IFN-gamma) or were not detected at all with either type of tumor recipient (IL-4). By means of monoclonal antibody-mediated neutralization or enhancement of endogenous cytokine levels, IL-10 was found to serve an important role in the growth and rejection patterns of the transfected P815 derivatives. In addition to previous evidence for an IL-12 requirement in promoting anti-P815 reactivity, these data establish IL-10 as an important cytokine in permitting optimal expression of this reactivity, which apparently develops in the absence of a strong bias toward a type 1 or type 2 cytokine response. |
